Pelvic floor exercises are more effective in subjective and objective outcomes with biofeedback or verbal feedback .
Weight loss with diet and exercise , caffeine reduction , 25 - 50 % reduction in fluid intake , and pelvic floor muscle exercises with verbal instruction and or biofeedback were all efficacious .
Botulinum toxin A improves urge incontinence episodes , urgency , frequency , quality of life , nocturia , and urodynamic testing parameters .
Acupuncture  improves quality of life and urodynamic testing parameters .
Extracorporeal magnetic stimulation improves urodynamic parameters .
Mirabegron improves daily incontinence episodes , nocturia , number of daily voids , and urine volume per void , whereas solabegron improves daily incontinence episodes .
Short-term posterior tibial nerve stimulation is more efficacious than pelvic floor muscle training exercises and behavioral therapy for improving : urgency , urinary incontinence episodes , daily voids , volume per void , and overall quality of life .
Sacral neuromodulation is more efficacious than antimuscarinic treatment for subjective improvement of overactive bladder and quality of life .
Transvaginal electrical stimulation demonstrates subjective improvement in overactive bladder symptoms and urodynamic parameters .
Multiple therapies , including physical therapy , behavioral therapy , botulinum toxin A , acupuncture , magnetic stimulation , mirabegron , posterior tibial nerve stimulation , sacral neuromodulation , and transvaginal electrical stimulation , are efficacious in the treatment of overactive bladder
The purpose of the study was to determine the efficacy and safety of nonantimuscarinic treatments for overactive bladder .
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
BACKGROUND Mirabegron , a β(3)-adrenoceptor agonist , has been developed for the treatment of overactive bladder ( OAB ) . OBJECTIVE To assess the efficacy and tolerability of mirabegron versus placebo . DESIGN , SETTING , AND PARTICIPANTS Multicenter r and omised double-blind , parallel-group placebo- and tolterodine-controlled  phase 3 trial conducted in 27 countries in Europe and Australia in patients ≥ 18 yr of age with symptoms of OAB for ≥ 3 mo . INTERVENTION After a 2-wk single-blind placebo run-in period , patients were r and omised to receive placebo , mirabegron 50 mg , mirabegron 100 mg , or tolterodine extended release 4 mg orally once daily for 12 wk . OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Patients completed a micturition diary and quality -of-life ( QoL ) assessment s. Co- primary efficacy end points were change from baseline to final visit in the mean number of incontinence episodes and micturitions per 24h . The primary comparison was between mirabegron and placebo with a secondary comparison between tolterodine and placebo . Safety parameters included adverse events ( AEs ) , laboratory assessment s , vital signs , electrocardiograms , and postvoid residual volume . RESULTS AND LIMITATIONS A total of 1978 patients were r and omised and received the study drug .  Mirabegron 50-mg and 100-mg groups demonstrated statistically significant improvements ( adjusted mean change from baseline [ 95 % confidence intervals ] ) at the final visit in the number of incontinence episodes per 24h ( -1.57 [ -1.79 to -1.35 ] and -1.46 [ -1.68 to -1.23 ] , respectively , vs placebo -1.17 [ -1.39 to -0.95 ] ) and number of micturitions per 24h ( -1.93 [ -2.15 to -1.72 ] and -1.77 [ -1.99 to -1.56 ] , respectively , vs placebo -1.34 [ -1.55 to -1.12 ] ; p<0.05 for all comparisons ) . Statistically significant improvements were also observed in other key efficacy end points and QoL outcomes . The incidence of treatment-emergent AEs was similar across treatment groups . The main limitation of this study was the short ( 12-wk ) duration of treatment . CONCLUSIONS Mirabegron represents a new class of treatment for OAB with proven efficacy and good tolerability . TRIAL IDENTIFICATION : This study is registered at Clinical Trials.gov , identifier NCT00689104
Pelvic floor exercises are more effective in subjective and objective outcomes with biofeedback or verbal feedback .
Weight loss with diet and exercise , caffeine reduction , 25 - 50 % reduction in fluid intake , and pelvic floor muscle exercises with verbal instruction and or biofeedback were all efficacious .
Botulinum toxin A improves urge incontinence episodes , urgency , frequency , quality of life , nocturia , and urodynamic testing parameters .
Acupuncture  improves quality of life and urodynamic testing parameters .
Extracorporeal magnetic stimulation improves urodynamic parameters .
Mirabegron improves daily incontinence episodes , nocturia , number of daily voids , and urine volume per void , whereas solabegron improves daily incontinence episodes .
Short-term posterior tibial nerve stimulation is more efficacious than pelvic floor muscle training exercises and behavioral therapy for improving : urgency , urinary incontinence episodes , daily voids , volume per void , and overall quality of life .
Sacral neuromodulation is more efficacious than antimuscarinic treatment for subjective improvement of overactive bladder and quality of life .
Transvaginal electrical stimulation demonstrates subjective improvement in overactive bladder symptoms and urodynamic parameters .
Multiple therapies , including physical therapy , behavioral therapy , botulinum toxin A , acupuncture , magnetic stimulation , mirabegron , posterior tibial nerve stimulation , sacral neuromodulation , and transvaginal electrical stimulation , are efficacious in the treatment of overactive bladder
The purpose of the study was to determine the efficacy and safety of nonantimuscarinic treatments for overactive bladder .